Inventions disclosed are seldom ready for commercialization. To attract interest from angel investors, venture capital firms, and corporate/industry partners, requires derisking the technology. The following organizations solicit grant proposals to support proof of concept, prototype development, and early stage company development.
Because groundbreaking science is most valuable when it can be translated into products that are available to Texans, a crucial component of CPRIT's mission is to create and support infrastructure in Texas that accelerates the movement of new cancer drugs, diagnostics, and therapies from the laboratory to the patient.
- Company Relocation Product Development Award
- Texas Company Product Development Award
Application Period: Now Closed
The Office of Technology Commercialization offers mentoring and other support for Product Development applications. Interested investigators may contact the OTC for further discussion at http://otc.uthscsa.edu
The CDMRP fills research gaps by funding high impact, high risk and high gain projects that other agencies may not venture to fund. While individual programs are unique in their focus, all of the programs managed by the CDMRP share the common goal of advancing paradigm shifting research, solutions that will lead to cures or improvements in patient care, or breakthrough technologies and resources for clinical benefit. The CDMRP strives to transform healthcare for Service Members and the American public through innovative and impactful research.
Hallmarks of the CDMRP include:
- investing in groundbreaking research
- targeting critical gaps
- reviewing application using a two-tier formal review with no standing peer review panels and no "pay line"
- involving consumer advocates throughout the program cycle
- supporting both the next generation of researchers and established scientists
- funding the full pipeline of research development, including basic, translational, and clinical research
- fostering (or employing) collaboration and synergy
McDermott Legacy Fund (MLF)
The McDermott Legacy Fund is administered and managed by The Texas Technology Development Center (T3DC), a subsidiary of the Texas Research & Technology Foundation (TRTF). The fund is designed to provide San Antonio-based start-ups with risk capital to stimulate additional investments from Private Sources. For additional information on grant requirements, visit the T3DC website or contact the OTC.
The PFI:AIR-TT program supports research to overcome technology barriers or knowledge gaps in the transformation of fundamental science and engineering discoveries into market-valued solutions. Researchers are expected to develop a proof of concept, prototype, or scale-up of the prototype that addresses real-world constraints and provides a competitive value in a potential application space. During the course of the AIR-TT award, it is also expected that the team advances their understanding of business as it relates to their technology, and that students are engaged to learn about innovation and technology translation. By the end of the award period, the technology will be further down the path to commercialization. AIR-TT awards provide $200k for 18 months.
At his discretion, President William L. Henrich is supporting Proof-of-Concept awards from the endowment earnings of the Stella C. Herff Charitable Trust to catalyze development of inventions disclosed by UT Health San Antonio staff and faculty to the Office of Technology Commercialization.
The goal of the fund is to support early and conceptual stages of product development (therapeutics, devices, biologics, software, etc.) that are assessed to have a high probability for commercialization targeting patient care and health promotion.
Awards will be up to $25,000.
Eligibility Criteria: All tenure, tenure track, and research track Investigators can apply (including, adjunct, VA, postdoc trainee). An individual may submit no more than one project as a principal investigator and one as a co-investigator.
Requirement: An invention disclosure form must be submitted for the technology for which funding is being requested.
Funding Limits: The total maximum amount to be requested is $25,000.
Application Period: FY 2018 cycle to be announced in February 2018.
- October 2, 2017 - Deadline for disclosures to OTC for consideration
- December 11, 2017 - Deadline for PTEF PowerPoint Pitch Applications
- December 15, 2017 - Notifications sent to Investiagtor for Applications selected to advance fot formal PTEF Pitch Session
- December 15, 2017 to January 21, 2018 - OTC provides coaching for Investigators seeking guidance (by appointment only)
- January 31, 2018 & February 1, 2018 - PowerPoint Pitch Session Presentations by Investigators
- February 7, 2018 - PTEF Award Recipients announced
- March 1, 2018 - PTEF Awards Funds distributed to recipients
- August 31, 2018 - PTEF Award expires; all unused funds return to OTC. Reports due to OTC.
Pitch Day Presentation: January 31, 2018 & February 1, 2018
Interim & Final Reporting Requirements: A project update meeting and mid-term progress report will be requested by the Office of Technology. Each awardee is required to submit a Final Progress Report as noted in the award letter.
Proposal Submission: Applications are available now. Submit applications electronically to firstname.lastname@example.org. Enter in the email subject line: PTEF-2018. Guides to aid in completing the "pitch deck" application can be found on the Resources page.
Organized in September 2016, the Angel Network is in the early stage itself. The online application process is functional now. Submissions will be carefully screened and presented to local angel investors. The fund will target startups with a product ready to be scaled-up. Pitch deck presentations to angels and an inventors active engagement with the startup funded is expected. For additional information and to best position your application, contact the OTC.
NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs play a significant role in stimulating innovation. Among the 11 Federal agencies that participate in the SBIR program, the NIH is one of the largest funders of this program, and the largest Federal supporter of biomedical research.
The NIH SBIR Program is ideally suited for creating research opportunities for U.S. small businesses to stimulate technological innovation. Part of a complex innovation system, the NIH SBIR program provides dedicated funding for small businesses to conduct early-stage research and development to explore the feasibility of innovative ideas that may eventually result in products or services that will lead to better health for everyone. The NIH SBIR program is one means by which the NIH Institutes and Centers (ICs) accomplish their R&D objectives. A unique feature of the SBIR program is a focus on commercialization of the outcomes of research. Thus, the program serves to supplement the more basic and applied research programs of NIH.
The Targeted Technology Funds are focused on early stage investments in companies that can advance ground breaking or disruptive technologies to significantly improve the practice of medicine and patient outcomes. They also favor technologies that can positively improve the efficiency, cost, or functionality of the development and manufacture of life science products.
With $50M in committed capital, the UT Horizon Fund, created in 2011 by the UT System Board of Regents, is one of the leading university-sponsored strategic investment vehicles in the United States.